Niloofar Ataee - Islamic Azad University of Falavarjan , Isfahan ,Iran
Niusha Ataee - Biotechnology Division, Department of Biology, Shahi Ashrafi Esfahani Nonprofit University, Isfahan, Iran
Massoud Houshmand - Medical Genetic Department, National Institute for Genetic Engineering and Biotechnology
Nasrin Fatahi - Gene RAZ BUALI, Genetic and Biotechnology Academy, Isfahan, Iran

Myeloid acute leukemia is one of the types of leukemia this type of leukemia affects bone marrow or myelocyte cells and there is an acute process. With using different bioinformatics, we selected a tumor suppressor geneTET2, that is eliminated or mutated in patients with various myeloid cancer. TET2 expression of hematopoietic cells is the highest in granulocytes. healthy tissues, the expression of hematopoietic cells is the highest in granulocytes. Increased in accordance with the function in myelopoiesis. For this reason, NCBI, MiRWALK0.2, miRBase, miRNASNP, DAVID sites were used to find more bioinformatics information. Interaction between the target and the microRNA based on the 3`UTR binding region of the extracted microRNA site and in order to find the most relevant signal paths, DAVID was compiled and the paths associated with it were evaluated on the KEGG database. The Gibbs free energy for the interdiction between the has-miR-514a-3p and TET2 with allel A inregion of rs143847362 is -24.20 and Gibbs free energy for the interdiction between the has-miR-514a-3p and TET2 with allel G inregion of rs143847362 is -23.90 .Therefore, it is expected that at the specific site of rs143847362 in the presence of the G allele, hsa-miR-514-3p have less binding and inhibitory effect. Therefore, gene expression in these individuals with the G allele is predicted to increase and we expect the G allele to be more common in sick people. Therefore, given the oncogenic role of the gene and the KEGG pathway, it is expected to be less common frequent in patients with the A allele.

Myeloid cancer, TET2, rs143847362, Inhibitory effect